Back
Biogen Inc (BIIB)
BiotechnologyBIIB · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$220.57
+1.10%Weekly undervalued picks (like BIIB)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$8.79
ROE
7.7%
Gross margin
78.7%
Debt/Equity
0.35x
Revenue growth
1.9%
Biogen Inc — company intelligence
Earnings surprises
Q2 2026$3.60 vs $3.01 est+19.8%
Q1 2026$3.57 vs $2.83 est+26.3%
Q4 2025$1.99 vs $1.65 est+20.9%
Q3 2025$4.81 vs $3.96 est+21.5%
Analyst consensus · 43 analysts
29 Buy13 Hold1 Sell
Updated Aug 23, 2026
Insider activity · 90 days
9 buys2 sellsnet +12,859 shares
Minor LloydSell 593 · Aug 4, 2026
Minor LloydSell 593 · Aug 3, 2026
LANGER SUSANBuy 1,505 · Jun 9, 2026
Recent SEC filings
4 — Insider transaction reportAug 5, 2026
10-Q — Quarterly reportJul 29, 2026
8-K — Material event reportJul 29, 2026
Latest news
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating — ChartMill · 1w ago
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target — Benzinga · 1w ago
NovelMed Advances NM5072 for Multiple Ocular Disorders — Yahoo · 2w ago
Biogen (BIIB) Q2 2026 Earnings Call Transcript — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like BIIB)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.